steroidinduc
osteonecrosi
femor
head
sonfh
lead
collaps
femor
head
articular
dysfunct
incid
amongst
patient
receiv
steroid
treatment
exact
patholog
sonfh
still
unclear
might
relat
lipid
metabol
disord
abnorm
microcircul
insuffici
blood
suppli
inflamm
bone
marrow
mesenchym
stem
cell
osteogenesi
differenti
dysfunct
abnorm
blood
suppli
lead
apoptosi
osteocyt
osteoblast
follow
bone
loss
reduc
bone
miner
densiti
lipid
metabol
dysfunct
also
import
patholog
steroid
applic
may
lead
increas
blood
lipid
level
develop
intravascular
lipid
embol
microvasculatur
embol
accumul
might
affect
microcircul
increas
pressur
intramedullari
caviti
eventu
lead
death
bone
cell
longterm
mass
steroid
applic
critic
pathogenesi
sonfh
howev
patient
receiv
longterm
highdos
steroid
develop
sonfh
indic
individu
differ
occurr
sonfh
date
sever
metaanalys
publish
shown
activ
associ
sonfh
incid
howev
result
polymorph
still
disput
previou
research
report
singlenucleotid
polymorph
snp
appear
three
studi
indic
protect
effect
sonfh
allel
model
apob
mutat
promot
pathogenesi
sonfh
mthfr
correl
sonfh
incid
howev
heterogen
still
exist
previou
result
analysi
characterist
includ
studi
need
therefor
research
analyz
effect
primari
diseas
type
steroid
cumul
steroid
dosag
treatment
durat
result
two
author
independ
perform
literatur
search
pubm
embas
cochran
librari
chines
public
databas
includ
china
nation
knowledg
infrastructur
china
biolog
medicin
databas
china
scienc
period
databas
wanfang
databas
vip
journal
integr
platform
search
includ
studi
publish
juli
follow
term
use
search
strategi
hormon
glucocorticoid
steroid
corticosteroid
osteonecrosi
femor
femur
femori
whirlbon
polymorph
snp
genet
mutat
genotyp
allel
allel
variat
search
strategi
shown
supplementari
tabl
diverg
search
result
resolv
discuss
studi
includ
metaanalysi
met
follow
criteria
casecontrol
cohort
studi
compar
popul
suffer
sonfh
popul
suffer
steroid
treatment
studi
assess
associ
genet
polymorph
sonfh
studi
report
frequenc
specif
allel
effect
size
individu
genotyp
case
control
studi
exclud
analysi
follow
reason
noncasecontrol
noncohort
studi
case
group
includ
sonfh
patient
etiolog
sonfh
patient
report
separ
control
group
includ
onfh
popul
without
steroid
applic
healthi
popul
nonsnprel
studi
studi
famili
hered
studi
report
data
pertain
allel
frequenc
effect
size
addit
confer
report
editor
comment
review
case
report
academ
dissert
exclud
analysi
two
author
independ
extract
follow
data
elig
studi
first
author
name
public
year
research
locat
sampl
size
averag
subject
age
primari
diseas
steroid
type
cumul
steroid
dose
treatment
durat
gene
interest
averag
median
valu
cumul
steroid
dosag
group
report
estim
cumul
dose
gener
calcul
multipli
daili
averag
dose
treatment
durat
studi
fix
treatment
strategi
cumul
dosag
calcul
multipli
dosag
treatment
cycl
total
number
cycl
present
studi
defin
averag
bodi
surfac
area
averag
bodi
weight
kg
closedinterv
categori
valu
assign
dosag
durat
averag
median
midpoint
openinterv
categori
valu
estim
limit
valu
multipli
differ
type
steroid
use
includ
studi
necessari
convert
dose
differ
type
steroid
equival
dose
prednison
convers
standard
mg
prednison
mg
prednisolon
mg
methylprednisolon
mg
dexamethason
newcastleottawa
scale
no
valid
tool
evalu
qualiti
observ
studi
use
evalu
methodolog
qualiti
includ
studi
scale
includ
follow
three
subscal
select
compar
exposur
associ
analysi
perform
use
five
genet
model
allel
w
vs
domin
wwwm
vs
mm
recess
ww
vs
wmmm
heterozyg
wm
vs
mm
homozyg
ww
vs
mm
model
w
wild
allel
mutat
allel
odd
ratio
or
ci
use
assess
strength
associ
polymorph
sonfh
incid
statist
use
estim
degre
heterogen
amongst
studi
cochran
q
statist
also
taken
measur
betweenstudi
heterogen
gener
signific
level
p
suggest
exist
signific
heterogen
expand
test
sensit
q
test
p
randomeffect
model
use
otherwis
fixedeffect
model
use
attempt
use
multilevel
mixedeffect
logist
regress
model
expans
logist
regress
type
steroid
primari
diseas
drug
dose
appli
durat
snp
factor
differ
genotyp
variabl
includ
fix
effect
differ
studi
consid
random
effect
final
conduct
doserespons
metaanalysi
across
cumul
steroid
dosag
deriv
doserespons
curv
model
dose
use
restrict
cubic
spline
three
knot
fix
percentil
distribut
test
twotail
pvalu
less
consid
statist
signific
except
cochran
q
test
research
return
english
articl
chines
articl
remov
duplic
screen
titl
abstract
articl
exclud
full
text
articl
assess
amongst
studi
exclud
follow
reason
control
group
receiv
steroid
therapi
review
nonsnprel
studi
basic
studi
studi
without
frequenc
effect
size
result
nonsteroidrel
onfh
studi
case
report
micrornarel
studi
duplic
report
hered
sonfh
studi
ultim
includ
studi
assess
total
patient
metaanalysi
figur
tabl
studi
casecontrol
design
except
one
studi
cohort
design
primari
diseas
includ
organ
transplant
hematolog
diseas
system
lupu
erythematosu
sle
rheumatoid
arthriti
ra
nephrot
syndrom
ophthalm
diseas
addit
two
studi
wei
two
studi
weibao
fang
studi
masaaki
kyoko
includ
patient
group
assess
snp
no
score
rang
six
nine
point
overal
qualiti
observ
studi
ideal
tabl
detail
no
score
studi
shown
supplementari
tabl
amongst
preliminari
result
snp
includ
three
studi
allel
model
show
mutat
protect
effect
sonfh
ci
apob
heterozyg
model
ci
homozyg
model
ci
domin
model
ci
p
recess
model
ci
domin
model
ci
mutat
increas
risk
sonfh
mthfr
signific
relationship
sonfh
figur
snp
includ
analysi
appear
three
studi
analysi
perform
present
studi
use
multilevel
mixedeffect
logist
regress
model
detail
includ
studi
group
analysi
list
supplementari
tabl
result
multilevel
mixedeffect
regress
model
mutant
homozygot
mutant
carrier
could
significantli
protect
sonfh
steroid
applic
tt
vs
cc
genotyp
ci
tctt
vs
cc
ci
result
show
signific
chang
cumul
dosag
treatment
durat
accord
analys
categor
variabl
steroid
type
prednisoneus
popul
mutant
homozygot
signific
protect
effect
compar
wildtyp
popul
tt
vs
cc
ci
result
similar
methylprednisoloneprednisoneus
popul
tt
vs
cc
ci
analysi
primari
diseas
show
signific
result
note
studi
report
primari
diseas
type
includ
sever
type
primari
diseas
includ
categor
analysi
primari
diseas
figur
neg
result
chang
consid
cumul
dose
treatment
durat
categor
analysi
protect
effect
mutant
found
methylprednisoloneprednisoloneus
renal
transplant
popul
ci
howev
result
base
singl
studi
larg
standard
error
se
thu
result
need
confirm
figur
apob
mutat
increas
incid
sonfh
ct
vs
tt
ci
tt
vs
cc
ci
cttt
vs
cc
ci
p
figur
due
larg
number
zero
event
regress
result
converg
consid
cumul
dose
result
chang
consid
treatment
durat
addit
prednisoneus
methylprednisoloneprednisoloneus
popul
renal
transplant
patient
mutat
increas
risk
sonfh
apob
mutat
increas
risk
sonfh
ga
vs
gg
ci
figur
result
obvious
chang
consid
cumul
dose
treatment
durat
categor
analysi
mutat
increas
risk
sonfh
prednisoneus
popul
ci
p
methylprednisoloneprednisoloneus
renal
transplant
popul
ci
mthfr
signific
correl
mutat
sonfh
risk
ct
vs
cc
ci
tt
vs
cc
ci
cttt
vs
cc
ci
result
chang
consid
continu
categor
variabl
figur
mutat
protect
effect
sonfh
vs
ci
vs
ci
vs
ci
figur
result
differ
previou
result
previou
research
randomeffect
model
use
due
larg
heterogen
mixedeffect
model
adopt
research
result
chang
consid
cumul
dose
treatment
durat
categor
analysi
protect
effect
exist
prednisoneus
renal
transplant
popul
howev
signific
correl
methylprednisoloneprednisoloneus
popul
vs
ci
vs
ci
vs
ci
furthermor
sought
analyz
cumul
dosag
sonfh
risk
mutat
carrier
doserespons
metaanalysi
sonfnonfh
incid
mutat
carrier
obtain
steroid
use
therefor
minimum
dose
must
use
refer
whether
increas
dose
affect
sonfh
incid
must
assess
two
dose
assess
method
use
absolut
dose
multipl
dose
correl
cumul
dose
occurr
sonfh
mutat
carrier
dose
increas
risk
sonfh
decreas
absolut
dose
multipl
dose
figur
b
neg
correct
also
persist
homozyg
mutat
tt
genotyp
absolut
dose
multipl
dose
heterozyg
mutat
patient
ct
genotyp
absolut
dose
p
multipl
dose
p
supplementari
figur
wildtyp
popul
correl
dose
risk
sonfh
absolut
dose
multipl
dose
although
signific
correl
mutat
risk
sonfh
cumul
dose
mutant
popul
correl
occurr
sonfh
dose
increas
risk
sonfh
decreas
absolut
dose
multipl
dose
figur
neg
correct
mainli
persist
heterozyg
mutat
patient
gagt
genotyp
absolut
dose
multipl
dose
mutat
patient
aaattt
genotyp
absolut
dose
multipl
dose
supplementari
figur
wildtyp
popul
correl
dose
risk
sonfh
absolut
dose
multipl
dose
find
may
suggest
mutat
carrier
still
risk
sonfh
use
steroid
similar
wildtyp
popul
sonfh
occur
smalldos
steroid
applic
increas
steroid
dose
mutat
carrier
increas
rather
decreas
risk
sonfh
apob
although
sonfh
correl
dose
mutat
carrier
absolut
dose
multipl
dose
correl
also
found
wildtyp
popul
absolut
dose
multipl
dose
apob
correl
cumul
dose
sonfh
risk
mutat
carrier
absolut
dose
multipl
dose
wildtyp
popul
absolut
dose
multipl
dose
apob
homozyg
mutat
patient
analyz
separ
perform
doserespons
analysi
mthfr
due
small
number
includ
studi
mutat
protect
effect
sonfh
mutat
apob
increas
sonfh
risk
present
studi
analyz
effect
specif
characterist
primari
diseas
includ
patient
type
steroid
cumul
dosag
treatment
durat
outcom
howev
increas
variabl
factor
result
depend
result
singl
studi
reduc
stabil
result
howev
analys
perform
provid
addit
clue
research
direct
basic
clinic
research
studi
previou
research
analyz
associ
snp
sonfh
tradit
metaanalysi
three
snp
includ
ultim
apob
mthfr
includ
previou
metaanalys
one
studi
analyz
associ
gene
polymorph
sonfh
allel
identifi
may
reduc
risk
gcinduc
onfh
howev
studi
includ
report
found
correl
sonfh
result
anoth
metaanalysi
analyz
correl
gene
polymorph
sonfh
occurr
grade
method
assess
level
evid
result
show
could
reduc
occurr
sonfh
low
level
evid
apob
mutat
increas
risk
sonfh
moder
level
evid
result
studi
essenti
two
studi
except
howev
work
analyz
associ
snp
sonfh
base
steroid
type
primari
diseas
drug
dose
appli
durat
use
mixedeffect
logist
regress
model
also
conduct
doserespons
metaanalysi
analyz
cumul
dosag
sonfh
risk
mutat
carrier
work
expand
research
result
found
cumul
steroid
dosag
treatment
durat
littl
effect
result
doseeffect
correl
mutat
carrier
anoth
studi
analyz
associ
onfh
genet
polymorph
vascular
endotheli
growth
factor
endotheli
nitric
oxid
synthas
howev
includ
studi
contain
sonfh
onfhrel
studi
result
show
mutat
increas
risk
onfh
mutat
increas
risk
onfh
allel
model
error
present
studi
author
propos
mutat
increas
risk
onfh
data
show
reduc
risk
studi
analyz
sonfh
risk
onfh
differ
studi
present
studi
signific
correl
mutant
sonfh
prednisoneus
methylprednisoloneprednisoneus
popul
mutant
homozygot
protect
effect
methylprednisoloneprednisolon
renal
transplant
popul
apob
mutat
increas
incid
sonfh
prednisoneus
methylprednisoloneprednisoloneus
popul
renal
transplant
patient
apob
mutat
increas
risk
sonfh
prednisoneus
popul
mutat
protect
effect
sonfh
risk
prednisoneus
renal
transplant
popul
differ
outcom
differ
type
steroidus
popul
possibl
result
base
even
fewer
studi
differ
may
also
indic
differ
type
steroid
subtl
differ
affect
risk
sonfh
gener
believ
prednison
must
transform
activ
form
liver
prednisolon
requir
chang
may
reason
differ
result
two
drug
mutat
state
addit
evid
need
determin
whether
differ
result
type
steroid
apob
gene
polymorph
due
differ
effect
adipocyt
current
regist
studi
analyz
pharmacokinet
differ
steroid
children
result
yet
report
earlier
studi
also
report
cumul
dosag
methylprednisolon
prednison
correl
avascular
necrosi
incid
therefor
defin
steroid
type
evalu
genet
polymorph
sonfhrel
studi
although
report
effect
primari
diseas
sonfh
risk
focuss
influenc
steroid
use
diseas
treatment
also
report
renal
transplant
patient
cyclosporin
versu
tacrolimu
well
gender
factor
may
independ
risk
factor
avascular
necrosi
metaanalysi
avascular
necrosi
risk
sle
patient
also
show
addit
hormonotherapi
arthrit
cushingoid
hypertens
cytotox
drug
etc
also
affect
occurr
sonfh
therefor
primari
diseas
treatment
strategi
also
possibl
risk
factor
sonfh
incid
gener
believ
occurr
sonfh
due
longterm
andor
highdosag
steroid
applic
doserespons
metaanalysi
show
incid
osteonecrosi
correl
cumul
dose
treatment
durat
howev
still
relat
research
specif
mutant
carrier
first
present
studi
found
mutat
protect
effect
sonfh
risk
reduc
increas
cumul
steroid
dosag
also
conclud
mutant
carrier
sonfh
cumul
dosag
low
howev
sonfh
occur
risk
sonfh
increas
cumul
dose
steroid
increas
therefor
mutant
carrier
critic
time
period
prevent
diagnosi
sonfh
earli
stage
steroid
applic
late
stage
neg
correl
also
found
mutat
carrier
even
though
mutat
significantli
associ
sonfh
gener
present
studi
still
sever
limit
first
studi
perform
studi
level
instead
individu
level
second
stratifi
analys
increas
variabl
factor
result
becom
depend
result
singl
studi
reduc
stabil
result
third
doserespons
analys
sonfnonfh
incid
mutat
carrier
without
steroid
applic
calcul
therefor
minimum
dose
must
use
refer
fourth
studi
analyz
snp
examin
three
studi
emerg
research
evid
snp
may
studi
futur
therefor
present
studi
limit
research
avail
time
